M&A Deal Summary |
|
---|---|
Date | 2024-04-03 |
Target | SpineThera - cGMP Manufacturing Operational Assets |
Sector | Life Science |
Buyer(s) | ProMed |
Sellers(s) | SpineThera |
Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
ProMed is a contract manufacturer of polymer-based drug releasing dosage forms and combination device components. ProMed was founded in 1989 and is based in Plymouth, Minnesota.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (Minnesota) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2024) | 1 of 1 |
SpineThera, Inc. designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug. The company was incorporated in 2012 and is based in Plymouth, Minnesota.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
State (Minnesota) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2024) | 1 of 1 |